MarketCap
Facebook
X
Telegram
Country |
 Australia |
IPO year |
2017 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
231 M |
Market Cap[1] |
$ 219 M |
EBITDA (LTM) |
$ -5.34 M |
P/E (LTM) |
-0.460177 |
P/S (LTM) |
32.959277 |
EPS (LTM) |
-2.26 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Kymera Therapeutics
KYMR
|
$ 110.76 | -0.08 % | $ 9.36 B | Nasdaq Global Market |  USA |
 |
Oramed Pharmaceuticals
ORMP
|
$ 4.13 | 0.24 % | $ 171 M | Nasdaq Global Select Market |  Israel |
 |
Larimar Therapeutics
LRMR
|
$ 2.35 | 3.52 % | $ 195 M | Nasdaq Global Market | USA |
|
Phathom Pharmaceuticals
PHAT
|
$ 5.74 | -18.12 % | $ 419 M | Nasdaq Global Select Market,SPB | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 252.96 | -2.3 % | $ 5.69 B | Nasdaq Global Select Market,SPB | USA |
 |
PainReform Ltd.
PRFX
|
$ 0.74 | 2.76 % | $ 480 K | Nasdaq Capital Market | Israel |
 |
Protagonist Therapeutics
PTGX
|
$ 138.43 | -0.79 % | $ 8.8 B | Nasdaq Global Select Market | USA |
 |
Replimune Group
REPL
|
$ 11.46 | -4.42 % | $ 1.06 B | Nasdaq Global Select Market | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.11 | -4.31 % | $ 51.5 M | Nasdaq Capital Market | USA |
 |
REGENXBIO
RGNX
|
$ 6.68 | -6.83 % | $ 345 M | Nasdaq Global Select Market,SPB | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 29.36 | 0.58 % | $ 1.4 T | Nasdaq Global Select Market |  France |
 |
Viking Therapeutics
VKTX
|
$ 24.4 | -5.54 % | $ 2.75 B | Nasdaq Capital Market | USA |
 |
Seer
SEER
|
$ 1.97 | 0.51 % | $ 109 M | Nasdaq Global Select Market | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.21 | 0.45 % | $ 1.21 B | Nasdaq Global Market,SPB | USA |
|
Nuvation Bio
NUVB
|
$ 4.57 | -2.45 % | $ 1.56 B | NYSE | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.81 | -2.69 % | $ 2.37 M | Nasdaq Global Select Market | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 0.42 | 0.26 % | $ 5.18 B | Nasdaq Global Market | Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
$ 69.45 | 3.06 % | $ 193 M | Nasdaq Global Select Market | Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 11.54 | 1.67 % | $ 1.26 B | Nasdaq Capital Market | USA |
 |
Syndax Pharmaceuticals
SNDX
|
$ 13.4 | -1.25 % | $ 1.16 B | Nasdaq Global Select Market | USA |
 |
Relay Therapeutics
RLAY
|
$ 18.18 | -0.87 % | $ 3.12 B | Nasdaq Global Market | USA |
 |
Pfizer
PFE
|
$ 30.03 | -1.28 % | $ 171 B | NYSE,SPB | USA |
 |
Sutro Biopharma
STRO
|
$ 9.33 | -9.33 % | $ 79.3 M | Nasdaq Global Select Market | USA |
 |
Shattuck Labs
STTK
|
$ 5.49 | -1.96 % | $ 382 M | Nasdaq Global Select Market | USA |
 |
Revolution Medicines
RVMD
|
$ 186.99 | -0.37 % | $ 35.6 B | Nasdaq Global Select Market | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 89.27 | -1.79 % | $ 5.8 B | Nasdaq Global Market,SPB | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.63 | 0.83 % | $ 279 M | Nasdaq Global Select Market | USA |
 |
Sana Biotechnology
SANA
|
$ 2.33 | -1.69 % | $ 590 M | Nasdaq Global Select Market | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 2.02 | 2.54 % | $ 1.36 B | Nasdaq Capital Market | Israel |
 |
Pulmatrix
PULM
|
$ 1.48 | 4.23 % | $ 5.41 B | Nasdaq Global Select Market | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 15.65 | -1.88 % | $ 1.54 B | Nasdaq Global Select Market,SPB | USA |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | USA |
|
Protara Therapeutics
TARA
|
$ 2.33 | -4.51 % | $ 99.8 M | Nasdaq Global Market | USA |
 |
AC Immune SA
ACIU
|
$ 2.42 | -3.2 % | $ 244 M | Nasdaq Global Market |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | USA |
 |
Adagene
ADAG
|
$ 2.41 | -1.23 % | $ 142 M | Nasdaq Global Market |  China |
 |
Adial Pharmaceuticals
ADIL
|
$ 3.92 | -7.11 % | $ 2.62 M | Nasdaq Capital Market | USA |
 |
Zai Lab Limited
ZLAB
|
$ 24.03 | 9.03 % | $ 26.3 B | Nasdaq Global Select Market | China |
 |
ADMA Biologics
ADMA
|
$ 10.68 | -2.47 % | $ 2.55 B | Nasdaq Global Market | USA |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 2.21 | -8.3 % | $ 159 M | Nasdaq Global Market | USA |
 |
Zymeworks
ZYME
|
$ 28.22 | -0.77 % | $ 1.45 B | NYSE |  Canada |
 |
Zoetis
ZTS
|
$ 81.03 | -1.18 % | $ 35.9 B | NYSE,SPB | USA |
 |
Assembly Biosciences
ASMB
|
$ 19.84 | -2.17 % | $ 222 M | Nasdaq Global Select Market,SPB | USA |
 |
Allogene Therapeutics
ALLO
|
$ 1.25 | -1.6 % | $ 276 M | Nasdaq Global Select Market,SPB | USA |
 |
Amgen
AMGN
|
$ 439.26 | -1.79 % | $ 236 B | Nasdaq Global Select Market,SPB | USA |
 |
Ardelyx
ARDX
|
$ 3.08 | -3.75 % | $ 742 M | Nasdaq Global Market | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.64 | 5.51 % | $ 132 M | NYSE American | USA |
 |
Artelo Biosciences
ARTL
|
$ 2.55 | 2.75 % | $ 482 K | Nasdaq Global Select Market | USA |
 |
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market |  Germany |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.55 | -2.47 % | $ 246 M | Nasdaq Global Select Market |  Britain |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.